🇺🇸 FDA
Patent

US 11319375

Methods and compositions for treating subjects having rheumatoid arthritis

granted A61KA61K2039/505A61K2039/545

Quick answer

US patent 11319375 (Methods and compositions for treating subjects having rheumatoid arthritis) held by REGENERON PHARMACEUTICALS, INC. expires Mon Apr 28 2042 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.

Key facts

Applicant
REGENERON PHARMACEUTICALS, INC.
Grant date
Tue May 03 2022 00:00:00 GMT+0000 (Coordinated Universal Time)
Expiration
Mon Apr 28 2042 00:00:00 GMT+0000 (Coordinated Universal Time)
Claims
13
CPC classes
A61K, A61K2039/505, A61K2039/545, A61K39/395, A61K39/3955